August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant

August 19, 2025

Bedtime Cyclobenzaprine Relieves Fibromyalgia: Randomized Trial

Researchers found bedtime sublingual cyclobenzaprine reduced pain versus placebo and improved sleep, fatigue, and function with mostly mild oral adverse events.

Conexiant

August 15, 2025

FDA Approves Non-Opioid Fibromyalgia Therapy

Tonmya reduces fibromyalgia pain versus placebo in phase 3 trials, offering a non-opioid option with a generally well-tolerated safety profile.

Conexiant

August 11, 2025

FDA Approves Ketamine Product for Surgical Pain Management

PharmaTher has received FDA approval for KETARx, a ketamine therapy for surgical pain management.

Conexiant

July 31, 2025

FDA Approves Implantable Device for RA

“The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases."

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

June 12, 2024

USPSTF Releases Draft Osteoporosis Screening Guidelines

The USPSTF's draft recommendations reaffirm osteoporosis screening for older women, call for more research on screening men, and address health disparities.

Conexiant

September 30, 2024

Lupus Treatment Trial Paused Following Patient Deaths

Three of the fatalities showed a common pattern of symptoms and the deaths happened close to the time of dosing, while a non-fatal adverse event showed a similar proximity to dosing.

Reuters

June 20, 2024

FDA Proposes Removal of Switching Study Requirement for Biosimilars

Explore the FDA's proposed changes for biosimilar drugs and their interchangeability, including expert insights on regulatory impacts and market dynamics.

Reuters